Clinic outcome of gefitinib as the first line treatment in elderly patients with lung adenocarcinoma
10.3760/cma.j.issn.1006-9801.2013.05.006
- VernacularTitle:吉非替尼一线治疗70岁以上肺腺癌的临床分析
- Author:
Ruotian WANG
;
Xiuyi ZHI
;
Yi ZHANG
;
Shuyang YAO
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Gefitinib;
First-line treatment;
Elderly
- From:
Cancer Research and Clinic
2013;(5):306-308
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and adverse effects of gefitinib as the first line treatment in elderly patients with lung adenocarcinoma.Methods 81 elderly patients of previously untreated advanced lung adenocarcinoma,who were non-smokers and unsuitable for chemotherapy,received gefitinib treatment until disease progression or intolerable toxicities occurred.The curative effect performance status of improvement and adverse effects were observed.Results All of the patients were evaluable.Partial response rate and stable disease rate of gefifinib were 25.9 ％ (21/81) and 48.1％ (39/81),respectively.55.5 ％ (45/81)of patients had performance status improved after treatment.Conclusion Gefitinib has curative effect and is well tolerated in the treatment of elderly patients with previously untreated advanced lung adenocarcinoma.
